Cyclerion Therapeutics Stock Price, News & Analysis (NASDAQ:CYCN)

Cyclerion Therapeutics trades on the NASDAQ under the ticker symbol "CYCN."

Cyclerion Therapeutics Inc (NASDAQ:CYCN) announced its earnings results on Monday, August, 12th. The company reported ($1.18) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.84) by $0.34. The firm earned $1.63 million during the quarter. View Cyclerion Therapeutics' Earnings History.

Cyclerion Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November 11th 2019. View Earnings Estimates for Cyclerion Therapeutics.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclerion Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cyclerion Therapeutics.

News headlines about CYCN stock have trended negative on Sunday, InfoTrie reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cyclerion Therapeutics earned a daily sentiment score of -2.6 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Cyclerion Therapeutics.

Cyclerion Therapeutics saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 1,230,000 shares, an increase of 10.8% from the August 30th total of 1,110,000 shares. Based on an average daily trading volume, of 109,700 shares, the days-to-cover ratio is currently 11.2 days. Currently, 4.7% of the company's stock are short sold. View Cyclerion Therapeutics' Current Options Chain.

Some companies that are related to Cyclerion Therapeutics include Amphastar Pharmaceuticals (AMPH), Epizyme (EPZM), Odonate Therapeutics (ODT), Athenex (ATNX), Y-mAbs Therapeutics (YMAB), Amneal Pharmaceuticals (AMRX), ANI Pharmaceuticals (ANIP), Phibro Animal Health (PAHC), G1 Therapeutics (GTHX), Eagle Pharmaceuticals (EGRX), Spectrum Pharmaceuticals (SPPI), Dova Pharmaceuticals (DOVA), Endo International (ENDP), CannTrust (CNTTF) and Emisphere Technologies (EMIS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclerion Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Abeona Therapeutics (ABEO), Arbutus Biopharma (ABUS), ACADIA Pharmaceuticals (ACAD), Aclaris Therapeutics (ACRS), AcelRx Pharmaceuticals (ACRX), ADMA Biologics (ADMA), Adamas Pharmaceuticals (ADMS), Aduro BioTech (ADRO) and Adverum Biotechnologies (ADVM).

Shares of CYCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CYCN stock can currently be purchased for approximately $8.67.

Cyclerion Therapeutics has a market capitalization of $237.73 million. View Additional Information About Cyclerion Therapeutics.

The official website for Cyclerion Therapeutics is http://www.cyclerion.com/.

Cyclerion Therapeutics' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The company can be reached via phone at 857-327-8778 or via email at [email protected]